COVID-19
Conditions
Keywords
COVID-19, Deferoxamine
Brief summary
In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.
Interventions
DRUGDeferoxamine
Intravenous infusion of Deferoxamine
Sponsors
Kermanshah University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
3 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
Clinical diagnosis of COVID-19 Disease,
Exclusion criteria
Previous history of allergy to Deferoxamin, Pregnancy, kidney dysfunction,
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality rate | up to 20 days | All cause of death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in patients PaO2 | up to 20 days | — |
| Length of hospitalization | up to 20 days | days |
| change in patients clinical manifestation | up to 20 days | Mild, Moderate or Severe |
| lymphocyte count | up to 20 days | — |
| length of intensive care unit stay | 1 to 20 days | — |
| C-reactive protein | up to 20 days | — |
Countries
Iran
Contacts
Primary ContactAlireza Ghaffarieh, MD
Backup ContactYadollah Shakiba, MD, PhD
Outcome results
None listed